Biotech China 2014

Approval of Additional Indications for the immunosuppressant Prograf® for Ulcerative Colitis in Japan

Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for moderately/severely refractory (steroid resistance and steroid dependency ) ulcerative colitis as additional indication for the immunosuppressant Prograf® (generic name: tacrolimus hydrate), submitted an sNDA to the Pharmaceuticals and Medical Devices Agency (PMDA) in June 2008 in Japan.

http://www.astellas.com/en/corporate/news/detail/approval-of-additional-indicat.html



Comments

POSTED:2014-03-25 18:59:35

AUTHOR: GUEST

erica,I am really<a href="http://ipsjhf.com"> isseemprd</a> by your hardwork for being FIT!would you mind to share some tips with us..actually our background is very similar,I am studyin in USA as well (east coast )lol... But for me it's so hard to keep fit.. I am 5 6'tall and about 125lbs ...oh god wish u can help me !!


POSTED:2014-03-25 12:26:53

AUTHOR: GUEST

Learning a ton from these neat arceltis.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.